Verona Pharma PLC
NASDAQ:VRNA

Watchlist Manager
Verona Pharma PLC Logo
Verona Pharma PLC
NASDAQ:VRNA
Watchlist
Price: 35.37 USD -4.22% Market Closed
Market Cap: 2.9B USD
Have any thoughts about
Verona Pharma PLC?
Write Note

Verona Pharma PLC
Stock-Based Compensation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Verona Pharma PLC
Stock-Based Compensation Peer Comparison

Comparables:
GSK
AZN
INDV
HIK
DPH

Competitive Stock-Based Compensation Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Verona Pharma PLC
NASDAQ:VRNA
Stock-Based Compensation
$32.1m
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
AstraZeneca PLC
LSE:AZN
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dechra Pharmaceuticals PLC
LSE:DPH
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Verona Pharma PLC's Stock-Based Compensation?
Stock-Based Compensation
32.1m USD

Based on the financial report for Sep 30, 2024, Verona Pharma PLC's Stock-Based Compensation amounts to 32.1m USD.

What is Verona Pharma PLC's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 3Y
-2%

Over the last year, the Stock-Based Compensation growth was 69%. The average annual Stock-Based Compensation growth rates for Verona Pharma PLC have been -2% over the past three years .

Back to Top